DS-1055 / Daiichi Sankyo - LARVOL DELTA

Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma. (PubMed, Leukemia) - "DS-1055a, an anti-GARP monoclonal antibody, selectively and effectively depleted malignant ATL cells via antibody-dependent cellular cytotoxicity, supporting the proof-of-concept in the preclinical study. Our findings highlight the key to understanding the cell origin of ATL and developing unprecedented therapeutic strategies for refractory diseases."

Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TGFB1

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Enrollment closed • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025

Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial primary completion date: Mar 2023 ➔ Dec 2024

Metastases • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

[VIRTUAL] Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells (AACR 2021) - P1 | "From these results, we propose that DS-1055a can be a new Treg cell-targeted regent that augments antitumor T cell immunity by depleting GARP+ Treg cells. Currently, a Phase I study of DS-1055a is on-going (NCT04419532)."

Oncology • CD4 • CD8 • FOXP3

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial completion date: Mar 2023 ➔ Dec 2024

Metastases • Trial completion date • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor

"SVB cites one other anti-GARP in clinical development, $DSNKY's DS-1055a" (@ByMadeleineA)

Clinical

Novel anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP + regulatory T cells. (PubMed, Int Immunol) - "Moreover, DS-1055a decreased FoxP3 +CD4 + T cells in the TME and exhibited remarkable antitumor activity in a humanized mouse bearing HT29 tumor. We propose that DS-1055a is a new Treg-cell-targeted cancer immunotherapy agent with augmentation of antitumor immunity."

Journal • Immune Modulation • Immunology • Inflammation • Oncology • CD4 • FOXP3

"uh-huh 1847 - Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells #AACR21" (@PDRennert)

Oncology

Use of Autochthonous Lactiplantibacillus plantarum Strains to Produce Fermented Fish Products. (PubMed, Front Microbiol) - "plantarum 11, L. plantarum 69, and L. plantarum DSM1055) at 10 cfu/g and incubated at 10, 20, or 30°C for 7 days...In the second step, salami-like were produced according to the individuated formulation and inoculated with the studied starters (10 cfu/g); the fish mixture was stuffed into a natural casing and left to ferment at 30°C for 7 days. The use of the selected strains not only assured a correct fermentation but reduced the process time at only 2 days; during refrigerated storage, a good microbiological, chemico-physical and sensorial quality of the final product was recorded for at least 21 days."

Journal

BioInvent receives €2 million milestone from Daiichi Sankyo (PRNewswire) - "BioInvent...today announces that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant (GARP) directed antibody...in adult patients with advanced or metastatic solid tumors."

Financing • Oncology • Solid Tumor

Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells (Businesswire) - "Daiichi Sankyo...announced today that the first patient has been dosed in a first-in-human global phase 1 study evaluating DS-1055, a GARP directed immuno-oncology therapy, in patients with advanced or metastatic solid tumors who have progressed on standard treatments including checkpoint inhibitors."

Trial status • Oncology • Solid Tumor

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Daiichi Sankyo Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1; N=40; Not yet recruiting; Sponsor: Daiichi Sankyo Co., Ltd.

Clinical • New P1 trial • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor